BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31417180)

  • 41. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
    Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
    Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
    Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
    Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human T-ALL Xenografts.
    Fuentes P; Toribio ML; González-García S
    Methods Mol Biol; 2021; 2185():215-239. PubMed ID: 33165851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia.
    Paganelli F; Lonetti A; Anselmi L; Martelli AM; Evangelisti C; Chiarini F
    Adv Biol Regul; 2019 Dec; 74():100649. PubMed ID: 31523031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.
    Gao X; Qin S; Wu Y; Chu C; Jiang B; Johnson RH; Kuang D; Zhang J; Wang X; Mehta A; Tew KD; Leone GW; Yu XZ; Wang H
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34255748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microenvironmental cues for T-cell acute lymphoblastic leukemia development.
    Passaro D; Quang CT; Ghysdael J
    Immunol Rev; 2016 May; 271(1):156-72. PubMed ID: 27088913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.
    Poglio S; Lewandowski D; Calvo J; Caye A; Gros A; Laharanne E; Leblanc T; Landman-Parker J; Baruchel A; Soulier J; Ballerini P; Clappier E; Pflumio F
    Oncotarget; 2016 Jul; 7(27):41599-41611. PubMed ID: 27191650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
    Pikman Y; Ocasio-Martinez N; Alexe G; Dimitrov B; Kitara S; Diehl FF; Robichaud AL; Conway AS; Ross L; Su A; Ling F; Qi J; Roti G; Lewis CA; Puissant A; Vander Heiden MG; Stegmaier K
    Leukemia; 2022 Feb; 36(2):348-360. PubMed ID: 34341479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow.
    Naresh KN; May PC; Reid AG; Marks AJ; Macdonald D; Kanfer E
    Histopathology; 2010 Oct; 57(4):549-54. PubMed ID: 20875071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
    Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
    Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth of human T cell acute lymphoblastic leukemia lymphoblasts in NOD/SCID mouse fetal thymus organ culture.
    Ma F; Manabe A; Wang D; Ito M; Kikuchi A; Wada M; Ito M; Ohara A; Hosoya R; Asano S; Tsuji K
    Leukemia; 2002 Aug; 16(8):1541-8. PubMed ID: 12145696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses.
    Fabricius D; Breckerbohm L; Vollmer A; Queudeville M; Eckhoff SM; Fulda S; Strauss G; Debatin KM; Jahrsdörfer B; Meyer LH
    Leukemia; 2011 Jul; 25(7):1111-21. PubMed ID: 21527935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
    Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
    Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia.
    García-Cañaveras JC; Lancho O; Ducker GS; Ghergurovich JM; Xu X; da Silva-Diz V; Minuzzo S; Indraccolo S; Kim H; Herranz D; Rabinowitz JD
    Leukemia; 2021 Feb; 35(2):377-388. PubMed ID: 32382081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis.
    Silic-Benussi M; Scattolin G; Cavallari I; Minuzzo S; Del Bianco P; Francescato S; Basso G; Indraccolo S; D'Agostino DM; Ciminale V
    Cell Death Dis; 2018 Aug; 9(8):822. PubMed ID: 30069011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
    Li Z; Younger K; Gartenhaus R; Joseph AM; Hu F; Baer MR; Brown P; Davila E
    J Clin Invest; 2015 Mar; 125(3):1081-97. PubMed ID: 25642772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
    Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
    Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.